Physician profile
Brian Candell
NPI 1164581575
$7,104.40
in general payments reported to CMS, 2019-2025
43 companies · $666 in 2025
The $666 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $794 · 2020: $1,284 · 2021: $1,373 · 2022: $1,041 · 2023: $1,054 · 2024: $892 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,611.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $942.94 | 2019-2025 | |
| Novo Nordisk INC | $836.61 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $554.62 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Abbvie INC. | $499.50 | 2019-2025 | Ubrelvy, Vraylar, Synthroid |
| Insmed, INC. | $426.09 | 2019-2024 | Arikayce |
| Janssen Pharmaceuticals, INC | $387.20 | 2019-2023 | Xarelto |
| Amarin Pharma, INC. | $373.45 | 2020-2021 | |
| Amgen INC. | $294.60 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $294.40 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $283.95 | 2019-2025 | Shingrix, Arexvy, Boostrix |
| Takeda Pharmaceuticals U.S.A., INC. | $234.69 | 2019-2025 | Hyqvia, Cuvitru |
| E.R. Squibb & Sons, L.L.C. | $208.34 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $184.20 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Biohaven Pharmaceuticals, INC. | $178.51 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $142.35 | 2023-2025 | Farxiga, Breztri, Airsupra |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Candell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.